徐穎潔 研究員
癌癥靶向及mRNA療法應(yīng)用研究組
電話：63846590-776492
郵箱：[email protected]
研究方向
1.介導(dǎo)癌癥轉(zhuǎn)移及耐藥的分子靶點發(fā)現(xiàn),機制探究和靶向治療評估
2.優(yōu)化mRNA的體外合成與體內(nèi)遞送
3. 研發(fā)基于mRNA的治療應(yīng)用:包括癌癥mRNA疫苗,感染性疾病mRNA疫苗, mRNA的蛋白替代療法在癌癥及其他疾病中的應(yīng)用
個人簡歷
徐穎潔, 博士，課題組長，博士生導(dǎo)師。本科及碩士畢業(yè)于上海第二醫(yī)科大學(xué)臨床醫(yī)學(xué)七年制英文班，2011年在加拿大麥吉爾大學(xué)實驗醫(yī)學(xué)系獲得博士學(xué)位，2011-2017年于美國哈佛醫(yī)學(xué)院波士頓兒童醫(yī)院從事博士后研究。2017年7月加入上海交通大學(xué)醫(yī)學(xué)院生物化學(xué)和細(xì)胞分子生物學(xué)系擔(dān)任課題組長。
科研項目
國家自然科學(xué)基金面上項目，81872345，PTEN的蛋白磷酸酶功能調(diào)控Foxk1的活性在前列腺癌發(fā)生中的作用與機制，2019.01-2022.12，在研，項目負(fù)責(zé)人
上海市科技計劃項目，18PJ1406700，Prohibitin復(fù)合體介導(dǎo)的肺癌耐藥作用機制和靶向，2018.07-2020.06，結(jié)題，項目負(fù)責(zé)人
上海交通大學(xué)醫(yī)學(xué)院-希伯來大學(xué)種子基金項目，抑制新冠病毒入侵的藥物篩選研究，2020.07-2023.06，在研，項目負(fù)責(zé)人
論文與專著
· Zhang J, Yin Y, Wang J, Zhang J, Liu H, Feng W, Yang W, Zetter B, Xu Y*. Prohibitin regulates mTOR pathway via the interaction with FKBP8. Frontiers of Medicine. 2020 (In press)
· Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T, Xu Y*, Lin J. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020, 30（936-939）. (*Co-corresponding author)
· Saw PE, Zhang A, Nie Y, Zhang L, Xu Y*, Xu X. Tumor-associated fibronectin targeted liposomal nanoplatform for cyclophilin A siRNA delivery and targeted malignant glioblastoma therapy. Frontier in Pharmacology. 2018 (*Co-corresponding author)
· Islam MA, Xu Y*, Tao,W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope HR,Yu M, Cao W, Oswald JT, Dinavand M, Mahmoudi M, Langer R, Kantoff PK, Farokhzad OC, Zetter BR, Shi J. Restoration of tumor suppression in vivo by systemic delivery of chemically modified PTEN mRNA nanoparticles. Nat. Biomed. Eng.2018 Sep 18 online. (*Co-first author)
· Yang W, Nagasawa K, Münch C, Xu Y, Satterstrom K, Jeong S, Hayes SD, Jedrychowski MP, Vyas FS; Zaganjor E, Guarani V, Ringle A, Gygi SP, Harper JW, Haigis MC. Mitochondrial Sirtuin Network Reveals Dynamic SIRT3-dependent Deacetylation in Response to Membrane Depolarization. Cell. 2016 Nov; 4(167):985-1000
· Xu Y, Yang W, Shi J, Zetter BR. Prohibitin 1 regulates tumor cell apoptosis via interaction with X-linked Inhibitor of Apoptosis Protein. J Mol Cell Biol. 2016 Jun; 8(3):282-5. doi: 10.1093/jmcb/mjw018.
· Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J. Biomaterial for mRNA delivery. Biomater Sci. 2015 Dec 10;3(12):1519-33. doi: 0.1039/c5bm00198f. Epub 2015 Aug 17.
· Zhu X, Xu Y*, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7779-84. (*Co-first author)
· Shi J, Xu Y*, Xu X, Zhu X, Pridgen E, Wu J, Alexander V, Zetter BR, Farokhzad O. Hybrid Lipid-Polymer Nanoparticles for Sustained siRNA Delivery and Gene Silencing. Nanomedicine. 2014 Mar 17. pii: S1549-9634(14)00124-5. doi: 10.1016/j.nano.2014.03.006. (*Co-first author)
· Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med. 2010 Oct 25;207(11):2421-37. Epub 2010 Oct 11.
· Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. Epub 2009 Oct 6.
· Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res. 2009 May;8(5):2173-85.
· Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Br J Cancer. 2009 Feb 24;100(4):633-43. Epub 2009 Feb 3.
· Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008 Nov;173(5):1540-50. Epub 2008 Oct 2.
· Benlimame N, He Q, Jie S, Xiao D, Xu Y, Loignon M, Schlaepfer DD, Alaoui-Jamali MA. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol. 2005 Nov 7;171(3):505-16.
